Johnson & Johnson (JNJ)
ETFs to Buy Post JNJ's Q4 Earnings Surprise & Bullish Cash Flow View
JNJ beat Q4 earnings and sales estimates and sees 2026 free cash flow rising to $21B, making healthcare ETFs a safer way to play its momentum.
Johnson & Johnson Quietly Triggers a Trend Following Buy Signal
Johnson & Johnson NYSE: JNJ, amid the noise of Trump's Greenland agenda and renewed trade war fears, is quietly executing its healthcare strategy, growing revenue and widening margins, setting its stock up to continue trending higher. A recent earnings release and 2026 guidance update, though strong, triggered a price pullback and a trend-following opportunity.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Johnson & Johnson is doing 'great things for patients,' CFO says
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company's performance and President Donald Trump's healthcare agenda on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #johnsonandjohnson #jnj #healthcare #health #patients #innovation #pharma #medicine #trump #donaldtrump #business #economy #ceo #agenda
Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The segment slightly outpaced the healthcare solution provider's other segment, Innovative Medicine, whose worldwide operational sales were up 5.
Johnson & Johnson (JNJ) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.04 per share a year ago.
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, with AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) a direct beneficiary. As reported by J&J on Wednesday, Spravato's fourth quarter 2025 sales in treatment-resistant depression (TRD) rose 10% sequentially to $503 million worldwide.
J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
JNJ beat Q4 earnings and sales estimates as strong oncology drug growth, led by Darzalex, offset biosimilar pressure on Stelara.
Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts
Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026 guidance that was modestly ahead forecasts. For Q4, Johnson & Johnson reported sales of $24.6 billion, representing reported growth of 9.1% year-over-year and operational growth of 7.1%.
